Comparison of Model-based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic Parameters

Overview

Journal J Biopharm Stat

Specialties Pharmacology
Public Health

Date 2008 Nov 11

PMID 18991109

Citations 24

Authors

Julie Bertrand

Emmanuelle Comets

France Mentre

Affiliations

Soon will be listed here.

Abstract

We evaluate by simulation three model-based methods to test the influence of a single nucleotide polymorphism on a pharmacokinetic parameter of a drug: analysis of variance (ANOVA) on the empirical Bayes estimates of the individual parameters, likelihood ratio test between models with and without genetic covariate, and Wald tests on the parameters of the model with covariate. Analyses are performed using the FO and FOCE method implemented in the NONMEM software. We compare several approaches for model selection based on tests and global criteria. We illustrate the results with pharmacokinetic data on indinavir from HIV-positive patients included in COPHAR 2-ANRS 111 to study the gene effect prospectively. Only the tests based on the EBE obtain an empirical type I error close to the expected 5%. The approximation made with the FO algorithm results in a significant inflation of the type I error of the LRT and Wald tests.

Citing Articles

Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment.

Karatza E, Papachristos A, Sivolapenko G, Gonzalez D CPT Pharmacometrics Syst Pharmacol. 2022; 11(10):1328-1340.

PMID: 35851999 PMC: 9574729. DOI: 10.1002/psp4.12848.

Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling.

Zwep L, Duisters K, Jansen M, Guo T, Meulman J, Upadhyay P CPT Pharmacometrics Syst Pharmacol. 2021; 10(4):350-361.

PMID: 33792207 PMC: 8099445. DOI: 10.1002/psp4.12603.

In vivo and in silico characterization of apocynin in reducing organ oxidative stress: A pharmacokinetic and pharmacodynamic study.

Liu F, Fan L, Michael N, Li J Pharmacol Res Perspect. 2020; 8(4):e00635.

PMID: 32761799 PMC: 7406636. DOI: 10.1002/prp2.635.

Model Averaging in Viral Dynamic Models.

Goncalves A, Mentre F, Lemenuel-Diot A, Guedj J AAPS J. 2020; 22(2):48.

PMID: 32060662 DOI: 10.1208/s12248-020-0426-7.

Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models.

Buatois S, Ueckert S, Frey N, Retout S, Mentre F AAPS J. 2018; 20(3):56.

PMID: 29600418 DOI: 10.1208/s12248-018-0205-x.

References

Meerum Terwogt J, Malingre M, Beijnen J, Ten Bokkel Huinink W, Rosing H, Koopman F . Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 1999; 5(11):3379-84. View

Retout S, Comets E, Samson A, Mentre F . Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates. Stat Med. 2007; 26(28):5162-79. DOI: 10.1002/sim.2910. View

Wahlby U, Jonsson E, Karlsson M . Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001; 28(3):231-52. DOI: 10.1023/a:1011527125570. View

Comets E, Mentre F . Evaluation of tests based on individual versus population modeling to compare dissolution curves. J Biopharm Stat. 2001; 11(3):107-23. DOI: 10.1081/BIP-100107652. View

Fellay J, Marzolini C, Meaden E, Back D, Buclin T, Chave J . Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002; 359(9300):30-6. DOI: 10.1016/S0140-6736(02)07276-8. View

Sakaeda T, Nakamura T, Okumura K . MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull. 2002; 25(11):1391-400. DOI: 10.1248/bpb.25.1391. View

Kerbusch T, Wahlby U, Milligan P, Karlsson M . Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol. 2003; 56(6):639-52. PMC: 1884295. DOI: 10.1046/j.1365-2125.2003.01967.x. View

Marzolini C, Paus E, Buclin T, Kim R . Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004; 75(1):13-33. DOI: 10.1016/j.clpt.2003.09.012. View

Retout S, Mentre F . Optimization of individual and population designs using Splus. J Pharmacokinet Pharmacodyn. 2004; 30(6):417-43. DOI: 10.1023/b:jopa.0000013000.59346.9a. View

10.

Csajka C, Marzolini C, Fattinger K, Decosterd L, Telenti A, Biollaz J . Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 2004; 48(9):3226-32. PMC: 514769. DOI: 10.1128/AAC.48.9.3226-3232.2004. View

11.

Min D, Ellingrod V, Marsh S, Mcleod H . CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit. 2004; 26(5):524-8. DOI: 10.1097/00007691-200410000-00010. View

12.

Roe D . Comparison of population pharmacokinetic modeling methods using simulated data: results from the Population Modeling Workgroup. Stat Med. 1997; 16(11):1241-57; discussion 1257-62. DOI: 10.1002/(sici)1097-0258(19970615)16:11<1241::aid-sim527>3.0.co;2-c. View

13.

Innocenti F, Liu W, Chen P, Desai A, Das S, Ratain M . Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics. 2005; 15(5):295-301. DOI: 10.1097/01213011-200505000-00004. View

14.

Panhard X, Mentre F . Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials. Stat Med. 2005; 24(10):1509-24. DOI: 10.1002/sim.2047. View

15.

Brendel K, Legrand M, Taburet A, Baron G, Goujard C, Mentre F . Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. Fundam Clin Pharmacol. 2005; 19(3):373-83. DOI: 10.1111/j.1472-8206.2005.00315.x. View

16.

Kappelhoff B, Huitema A, Sankatsing S, Meenhorst P, van Gorp E, Mulder J . Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol. 2005; 60(3):276-86. PMC: 1884764. DOI: 10.1111/j.1365-2125.2005.02436.x. View

17.

Bodor M, Kelly E, Ho R . Characterization of the human MDR1 gene. AAPS J. 2005; 7(1):E1-5. PMC: 2751491. DOI: 10.1208/aapsj070101. View

18.

Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentre F . Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS. 2005; 19(18):2127-31. DOI: 10.1097/01.aids.0000196122.91633.04. View

19.

Henningsson A, Marsh S, Loos W, Karlsson M, Garsa A, Mross K . Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res. 2005; 11(22):8097-104. DOI: 10.1158/1078-0432.CCR-05-1152. View

20.

Beal S . Conditioning on certain random events associated with statistical variability in PK/PD. J Pharmacokinet Pharmacodyn. 2005; 32(2):213-43. DOI: 10.1007/s10928-005-0090-7. View